Photo Credit: Nemes Laszlo
The following is a summary of “Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders,” published in the February 2024 issue of Hematology by Liu et al.
Researchers conducted a retrospective study investigating the current treatment landscape and prognostic factors associated with chronic NK cell lymphoproliferative disorder (CLPD-NK).
They involved 18 patients with CLPD-NK, treated from September 2016 to September 2022, focusing on their clinical characteristics, treatment modalities, and prognosis.
The results showed 18 patients, 3 received chemotherapy, 5 underwent immune-related therapy, 1 received glucocorticoids alone, 5 were given granulocyte colony-stimulating factor, blood transfusion therapy, or anti-infection therapy, followed by observation and follow-up, and four were observed without treatment. While 15 patients survived, with 2 achieving complete remission (CR) and 7 achieving partial remission (PR), 1 progressing to Aggressive NK-cell leukemia (ANKL) but sustaining remission after multiple lines of treatment, 3 patients were not reviewed, 1 remaining in active disease, 3 developing hemophagocytic syndrome during treatment and eventually dying, with one showing optimistic Epstein–Barr virus (EBV) expression. The OSR stood at 83% in 5 years.
Investigators concluded that CLPD-NK patients revealed favorable outcomes for most, with poor prognosis linked to ANKL progression and hemophagocytic syndrome. Abnormal NK cells indicated high ANKL risk, while immunosuppressants and hormones proved effective therapies.
Source: tandfonline.com/doi/full/10.1080/16078454.2024.2307817